<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Ottesen | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/beardbaboon3/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/beardbaboon3/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Ottesen.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">2a7ae6b2e565f8d54b38c7b9382dbe55</guid>
				<title>Ottesen posted an update: The current COVID-19 pandemic situation has stimulated an [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42978/</link>
				<pubDate>Sun, 09 Feb 2025 12:15:46 -0800</pubDate>

									<content:encoded><![CDATA[<p>The current COVID-19 pandemic situation has stimulated an unplanned clinical research paradigm which is evident from the surge of clinical trial registrations and the increasing number of COVID-related publications. We aimed to explore the standards for research conduction, publications and retraction of articles related to COVID-19&hellip;<span class="activity-read-more" id="activity-read-more-42978"><a href="http://www.nationalboardinstitute.com/activity/p/42978/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4f243d5e4e2a85adb7e015ee4d8b976f</guid>
				<title>Ottesen posted an update: No Abstract available.



 Crohn's disease (CD) patients [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40171/</link>
				<pubDate>Thu, 06 Feb 2025 13:54:54 -0800</pubDate>

									<content:encoded><![CDATA[<p>No Abstract available.</p>
<p> Crohn&#8217;s disease (CD) patients who previously failed anti-tumor necrosis factor (TNF) therapy are at higher risk of treatment failure with subsequent biologics. This study aims to determine the effectiveness and safety of higher maintenance dose regimens of adalimumab compared with standard doses in CD patients who failed&hellip;<span class="activity-read-more" id="activity-read-more-40171"><a href="http://www.nationalboardinstitute.com/activity/p/40171/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a15ecf1293dfc9cce88e5b78c7410f1d</guid>
				<title>Ottesen posted an update: The Nobel Turing Challenge aims to develop a highly [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39397/</link>
				<pubDate>Wed, 05 Feb 2025 13:07:02 -0800</pubDate>

									<content:encoded><![CDATA[<p>The Nobel Turing Challenge aims to develop a highly autonomous AI system that can perform top-level science, indistinguishable from the quality of that performed by the best human scientists, where some of the discoveries may be worthy of Nobel Prize level recognition and beyond.Human malaria affects the vast majority of the world&#8217;s population&hellip;<span class="activity-read-more" id="activity-read-more-39397"><a href="http://www.nationalboardinstitute.com/activity/p/39397/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b2e0955b46aa161ad8acb9192519ad1e</guid>
				<title>Ottesen posted an update: RIG-I inhibition by TRBP did not require phosphorylation of [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36831/</link>
				<pubDate>Sun, 02 Feb 2025 12:07:10 -0800</pubDate>

									<content:encoded><![CDATA[<p>RIG-I inhibition by TRBP did not require phosphorylation of sites shown to be important for inhibiting PKR, nor did it involve PACT or PKR, but it did require the dsRNA-binding ability of TRBP. These findings open the door to a complex co-regulation of RIG-I, PKR, MDA5, miRNA processing, and interferon induction.Plants encode a large number of&hellip;<span class="activity-read-more" id="activity-read-more-36831"><a href="http://www.nationalboardinstitute.com/activity/p/36831/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6ecdb062f09c21539eaa2f18e97ac77f</guid>
				<title>Ottesen posted an update: In this fungal up-regulation, various lipase, antioxidant [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34939/</link>
				<pubDate>Fri, 31 Jan 2025 12:13:14 -0800</pubDate>

									<content:encoded><![CDATA[<p>In this fungal up-regulation, various lipase, antioxidant enzyme, and hydrolase genes were highly transcribed. The gene set enrichment analysis of the infected tick showed that many peptide synthesis processes including translation, peptide metabolism, ribonucleotide metabolism, and energy production processes that included ATP generation and ADP&hellip;<span class="activity-read-more" id="activity-read-more-34939"><a href="http://www.nationalboardinstitute.com/activity/p/34939/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8a4c84c3cf6b5bb2f7680fb76e146ff0</guid>
				<title>Ottesen became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28998/</link>
				<pubDate>Tue, 28 Jan 2025 12:24:50 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>